KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Depreciation and Depletion (2020 - 2025)

Boston Scientific (BSX) has disclosed Depreciation and Depletion for 6 consecutive years, with $137.0 million as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion rose 12.3% to $137.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $471.0 million through Dec 2025, up 14.32% year-over-year, with the annual reading at $471.0 million for FY2025, 14.32% up from the prior year.
  • Depreciation and Depletion hit $137.0 million in Q4 2025 for Boston Scientific, up from $117.0 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $137.0 million in Q4 2025 to a low of $76.0 million in Q1 2022.
  • Historically, Depreciation and Depletion has averaged $96.8 million across 5 years, with a median of $94.0 million in 2022.
  • Biggest five-year swings in Depreciation and Depletion: dropped 8.43% in 2022 and later rose 17.78% in 2025.
  • Year by year, Depreciation and Depletion stood at $98.0 million in 2021, then fell by 3.06% to $95.0 million in 2022, then grew by 9.47% to $104.0 million in 2023, then rose by 17.31% to $122.0 million in 2024, then rose by 12.3% to $137.0 million in 2025.
  • Business Quant data shows Depreciation and Depletion for BSX at $137.0 million in Q4 2025, $117.0 million in Q3 2025, and $111.0 million in Q2 2025.